Consolidated Statement of Changes in Stockholders' (Deficit) Equity - USD ($)
|
Total |
Fiscal Year To Date |
Preferred Stock [Member] |
Common Stock [Member] |
Treasury Stock [Member] |
Additional Paid-in Capital [Member] |
Accumulated Deficit [Member] |
| Beginning balance at May. 31, 2018 |
$ (13,157,971)
|
$ (13,157,971)
|
$ 92
|
$ 216,881
|
$ (159)
|
$ 159,764,611
|
$ (173,139,396)
|
| Beginning balance, shares at May. 31, 2018 |
|
|
92,100
|
216,881,790
|
159,011
|
|
|
| Acquisition of ProstaGene LLC |
0
|
0
|
$ 0
|
$ 0
|
$ 0
|
0
|
0
|
| Acquisition of ProstaGene LLC, shares |
|
|
0
|
0
|
0
|
|
|
| Issuance of stock payment shares |
0
|
0
|
$ 0
|
$ 0
|
$ 0
|
0
|
0
|
| Issuance of stock payment shares, shares |
|
|
0
|
0
|
0
|
|
|
| Issuance of stock for note payable redemption |
0
|
0
|
$ 0
|
$ 0
|
$ 0
|
0
|
0
|
| Issuance of stock for note payable redemption ,shares |
|
|
0
|
0
|
0
|
|
|
| Proceeds from registered direct offering |
985,000
|
985,000
|
$ 0
|
$ 1,970
|
$ 0
|
983,030
|
0
|
| Proceeds from registered direct offering, shares |
|
|
0
|
1,970,000
|
0
|
|
|
| Offering costs related to registered direct offering, value |
(75,151)
|
(75,151)
|
$ 0
|
$ 0
|
$ 0
|
(75,151)
|
0
|
| Offering costs related to registered direct offering, shares |
|
|
0
|
0
|
0
|
|
|
| Proceeds from private equity offering |
7,514,300
|
7,514,300
|
$ 0
|
$ 15,029
|
$ 0
|
7,499,271
|
0
|
| Proceeds from private equity offering, shares |
|
|
0
|
15,028,600
|
0
|
|
|
| Offering costs related to private equity offering |
(882,716)
|
(882,716)
|
$ 0
|
$ 0
|
$ 0
|
(882,716)
|
0
|
| Offering costs related to debt offering |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Debt discount and issuance costs related to offering |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Beneficial conversion feature on note payable and relative fair value associated with warrants |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Legal fees in connection with equity offerings |
(50,544)
|
(50,544)
|
0
|
0
|
0
|
(50,544)
|
0
|
| Offering costs related to public warrant tender offers |
(882,716)
|
|
|
|
|
|
|
| Stock-based compensation |
283,346
|
283,346
|
0
|
0
|
0
|
283,346
|
0
|
| Net loss |
(14,413,569)
|
(14,413,569)
|
0
|
0
|
0
|
0
|
(14,413,569)
|
| Ending balance at Aug. 31, 2018 |
(19,797,305)
|
(19,797,305)
|
$ 92
|
$ 233,880
|
$ (159)
|
167,521,847
|
(187,552,965)
|
| Ending balance, shares at Aug. 31, 2018 |
|
|
92,100
|
233,880,390
|
159,011
|
|
|
| Beginning balance at May. 31, 2018 |
(13,157,971)
|
(13,157,971)
|
$ 92
|
$ 216,881
|
$ (159)
|
159,764,611
|
(173,139,396)
|
| Beginning balance, shares at May. 31, 2018 |
|
|
92,100
|
216,881,790
|
159,011
|
|
|
| Net loss |
(28,718,950)
|
|
|
|
|
|
|
| Ending balance at Nov. 30, 2018 |
(8,063,924)
|
(8,063,924)
|
$ 92
|
$ 290,810
|
$ (159)
|
193,503,678
|
(201,858,345)
|
| Ending balance, shares at Nov. 30, 2018 |
|
|
92,100
|
290,808,960
|
159,011
|
|
|
| Beginning balance at Aug. 31, 2018 |
(19,797,305)
|
(19,797,305)
|
$ 92
|
$ 233,880
|
$ (159)
|
167,521,847
|
(187,552,965)
|
| Beginning balance, shares at Aug. 31, 2018 |
|
|
92,100
|
233,880,390
|
159,011
|
|
|
| Acquisition of ProstaGene LLC |
11,558,000
|
11,558,000
|
$ 0
|
$ 18,658
|
$ 0
|
11,539,342
|
0
|
| Acquisition of ProstaGene LLC, shares |
|
|
0
|
18,658,000
|
0
|
|
|
| Issuance of stock payment shares |
0
|
8,342
|
$ 0
|
$ 8,342
|
$ 0
|
(8,342)
|
0
|
| Issuance of stock payment shares, shares |
|
|
0
|
8,342,000
|
0
|
|
|
| Issuance of stock for note payable redemption |
0
|
0
|
$ 0
|
$ 0
|
$ 0
|
0
|
0
|
| Issuance of stock for note payable redemption ,shares |
|
|
0
|
0
|
0
|
|
|
| Proceeds from registered direct offering |
0
|
985,000
|
$ 0
|
$ 0
|
$ 0
|
0
|
0
|
| Proceeds from registered direct offering, shares |
|
|
0
|
0
|
0
|
|
|
| Offering costs related to registered direct offering, value |
0
|
(75,151)
|
$ 0
|
$ 0
|
$ 0
|
0
|
0
|
| Offering costs related to registered direct offering, shares |
|
|
0
|
0
|
0
|
|
|
| Proceeds from private equity offering |
14,964,285
|
22,478,585
|
$ 0
|
$ 29,930
|
$ 0
|
14,934,355
|
0
|
| Proceeds from private equity offering, shares |
|
|
0
|
29,928,570
|
0
|
|
|
| Offering costs related to private equity offering |
(1,693,354)
|
(2,576,070)
|
$ 0
|
$ 0
|
$ 0
|
(1,693,354)
|
0
|
| Offering costs related to debt offering |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Debt discount and issuance costs related to offering |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Beneficial conversion feature on note payable and relative fair value associated with warrants |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Legal fees in connection with equity offerings |
(25,652)
|
(76,195)
|
0
|
0
|
0
|
(25,652)
|
0
|
| Stock-based compensation |
1,227,140
|
1,510,486
|
0
|
0
|
0
|
1,227,140
|
0
|
| Net loss |
(14,305,380)
|
(28,718,950)
|
0
|
0
|
0
|
|
(14,305,380)
|
| Ending balance at Nov. 30, 2018 |
(8,063,924)
|
(8,063,924)
|
$ 92
|
$ 290,810
|
$ (159)
|
193,503,678
|
(201,858,345)
|
| Ending balance, shares at Nov. 30, 2018 |
|
|
92,100
|
290,808,960
|
159,011
|
|
|
| Issuance of stock payment shares |
|
|
$ 0
|
|
$ 0
|
|
|
| Issuance of stock payment shares, shares |
|
|
0
|
|
0
|
|
|
| Proceeds from registered direct offering |
|
|
$ 0
|
$ 10,728
|
$ 0
|
|
|
| Proceeds from registered direct offering, shares |
|
|
0
|
10,728,480
|
0
|
|
|
| Offering costs related to registered direct offering, value |
|
|
$ 0
|
$ 0
|
$ 0
|
|
|
| Offering costs related to registered direct offering, shares |
|
|
0
|
0
|
0
|
|
|
| Proceeds from public warrant tender offers |
|
|
$ 0
|
$ 2,018
|
$ 0
|
|
|
| Proceeds from public warrant tender offers (shares) |
|
|
0
|
2,018,000
|
0
|
|
|
| Inducement interest expense - public warrant tender offers |
0
|
|
|
|
|
|
|
| Offering costs related to Series C Preffered offering |
|
|
$ 0
|
$ 0
|
$ 0
|
|
|
| Legal fees in connection with equity offerings |
|
|
0
|
0
|
0
|
|
|
| Offering costs related to public warrant tender offers |
(121,079)
|
|
0
|
|
|
|
|
| Stock-based compensation |
|
|
0
|
0
|
0
|
|
|
| Net loss |
|
|
0
|
0
|
0
|
|
|
| Ending balance at Feb. 28, 2019 |
|
|
$ 92
|
$ 304,680
|
$ (159)
|
|
|
| Ending balance, shares at Feb. 28, 2019 |
|
|
92,100
|
304,679,081
|
159,011
|
|
|
| Proceeds from registered direct offering |
|
|
$ 0
|
$ 10,931
|
$ 0
|
|
|
| Proceeds from registered direct offering, shares |
|
|
0
|
10,931,000
|
0
|
|
|
| Proceeds from private equity offering |
|
|
$ 0
|
$ 0
|
$ 0
|
|
|
| Proceeds from private equity offering, shares |
|
|
0
|
0
|
0
|
|
|
| Offering costs related to private equity offering |
|
|
$ 0
|
$ 0
|
$ 0
|
|
|
| Proceeds from Series C Convertible Preferred offering |
|
|
$ 3
|
|
|
|
|
| Proceeds from Series C Convertible Preferred offering, shares |
|
|
3,246
|
|
|
|
|
| Dividends on Series C Convertible Preferred shares |
(37,351)
|
|
$ 0
|
0
|
0
|
|
|
| Legal fees in connection with equity offerings |
|
|
0
|
0
|
0
|
|
|
| Offering costs related to public warrant tender offers |
0
|
|
|
|
|
|
|
| Stock-based compensation |
|
|
0
|
0
|
0
|
|
|
| Net loss |
|
|
0
|
0
|
0
|
|
|
| Ending balance at May. 31, 2019 |
(8,914,060)
|
(8,914,060)
|
$ 95
|
$ 329,555
|
$ (159)
|
220,119,856
|
(229,363,407)
|
| Ending balance, shares at May. 31, 2019 |
|
|
95,346
|
329,554,763
|
159,011
|
|
|
| Issuance of stock for note payable redemption |
1,005,000
|
1,005,000
|
$ 0
|
$ 3,015
|
$ 0
|
1,001,985
|
0
|
| Issuance of stock for note payable redemption ,shares |
|
|
0
|
3,014,181
|
0
|
|
|
| Proceeds from registered direct offering |
2,255,800
|
2,255,800
|
$ 0
|
$ 5,640
|
$ 0
|
2,250,160
|
0
|
| Proceeds from registered direct offering, shares |
|
|
|
5,639,500
|
|
|
|
| Offering costs related to registered direct offering, value |
(260,208)
|
(260,208)
|
$ 0
|
$ 0
|
$ 0
|
(260,208)
|
0
|
| Offering costs related to registered direct offering, shares |
|
|
0
|
0
|
0
|
|
|
| Proceeds from public warrant tender offers |
11,900,260
|
11,900,260
|
$ 0
|
$ 45,376
|
$ 0
|
11,854,884
|
0
|
| Proceeds from public warrant tender offers (shares) |
|
|
0
|
45,375,923
|
0
|
|
|
| Proceeds from Series C Convertible Preferred offering |
1,754,000
|
1,754,000
|
$ 2
|
|
|
1,753,998
|
0
|
| Proceeds from Series C Convertible Preferred offering, shares |
|
|
1,754
|
|
|
|
|
| Offering costs related to Series C Preffered offering |
(197,460)
|
(197,460)
|
$ 0
|
$ 0
|
$ 0
|
(197,460)
|
0
|
| Dividends on Series C Convertible Preferred shares |
(110,826)
|
(110,826)
|
0
|
0
|
0
|
0
|
(110,826)
|
| Legal fees in connection with equity offerings |
(15,877)
|
(15,877)
|
0
|
0
|
0
|
(15,877)
|
0
|
| Offering costs related to public warrant tender offers |
(1,058,466)
|
(1,058,466)
|
0
|
|
|
(1,058,466)
|
0
|
| Stock-based compensation |
580,727
|
580,727
|
0
|
0
|
0
|
580,727
|
0
|
| Note conversion and extension fees, Value |
0
|
0
|
0
|
$ 0
|
$ 0
|
0
|
0
|
| Note conversion and extension fees, Shares |
|
|
|
0
|
0
|
|
|
| Exercise of option to repurchase common stock |
0
|
0
|
|
|
|
|
|
| Inducement interest expense - debt conversion |
2,430,514
|
2,430,514
|
0
|
$ 0
|
$ 0
|
2,430,514
|
0
|
| Net loss |
(16,163,999)
|
(16,163,999)
|
0
|
0
|
0
|
0
|
(16,163,999)
|
| Ending balance at Aug. 31, 2019 |
(6,794,595)
|
(6,794,595)
|
$ 97
|
$ 383,586
|
$ (159)
|
238,460,113
|
(245,638,232)
|
| Ending balance, shares at Aug. 31, 2019 |
|
|
97,100
|
383,584,367
|
159,011
|
|
|
| Beginning balance at May. 31, 2019 |
(8,914,060)
|
(8,914,060)
|
$ 95
|
$ 329,555
|
$ (159)
|
220,119,856
|
(229,363,407)
|
| Beginning balance, shares at May. 31, 2019 |
|
|
95,346
|
329,554,763
|
159,011
|
|
|
| Net loss |
(31,024,467)
|
|
|
|
|
|
|
| Ending balance at Nov. 30, 2019 |
(13,631,597)
|
(13,631,597)
|
$ 100
|
$ 399,316
|
$ (159)
|
246,618,030
|
(260,648,884)
|
| Ending balance, shares at Nov. 30, 2019 |
|
|
99,888
|
399,315,351
|
159,011
|
|
|
| Beginning balance at Aug. 31, 2019 |
(6,794,595)
|
(6,794,595)
|
$ 97
|
$ 383,586
|
$ (159)
|
238,460,113
|
(245,638,232)
|
| Beginning balance, shares at Aug. 31, 2019 |
|
|
97,100
|
383,584,367
|
159,011
|
|
|
| Issuance of stock for note payable redemption |
739,959
|
1,744,959
|
$ 0
|
$ 2,269
|
$ 0
|
737,690
|
0
|
| Issuance of stock for note payable redemption ,shares |
|
|
|
2,270,151
|
|
|
|
| Proceeds from registered direct offering |
4,409,500
|
6,665,300
|
$ 0
|
$ 13,461
|
$ 0
|
4,396,039
|
0
|
| Proceeds from registered direct offering, shares |
|
|
0
|
13,460,833
|
0
|
|
|
| Offering costs related to registered direct offering, value |
(73,690)
|
(333,898)
|
$ 0
|
$ 0
|
$ 0
|
(73,690)
|
0
|
| Offering costs related to registered direct offering, shares |
|
|
0
|
0
|
0
|
|
|
| Proceeds from public warrant tender offers |
0
|
11,900,260
|
$ 0
|
$ 0
|
$ 0
|
0
|
0
|
| Proceeds from public warrant tender offers (shares) |
|
|
0
|
0
|
0
|
|
|
| Proceeds from Series C Convertible Preferred offering |
2,788,000
|
4,542,000
|
$ 3
|
$ 0
|
$ 0
|
2,787,997
|
0
|
| Proceeds from Series C Convertible Preferred offering, shares |
|
|
2,788
|
0
|
0
|
|
|
| Offering costs related to Series C Preffered offering |
(181,722)
|
(379,182)
|
$ 0
|
$ 0
|
$ 0
|
(181,722)
|
0
|
| Dividends on Series C Convertible Preferred shares |
(150,184)
|
(261,010)
|
0
|
0
|
0
|
0
|
(150,184)
|
| Legal fees in connection with equity offerings |
0
|
(15,877)
|
0
|
0
|
0
|
0
|
0
|
| Offering costs related to public warrant tender offers |
0
|
(1,058,466)
|
0
|
0
|
0
|
0
|
0
|
| Stock-based compensation |
434,245
|
1,014,972
|
0
|
0
|
0
|
434,245
|
0
|
| Note conversion and extension fees, Value |
(216,800)
|
(216,800)
|
$ 0
|
$ 0
|
$ 0
|
(216,800)
|
0
|
| Note conversion and extension fees, Shares |
|
|
0
|
0
|
0
|
|
|
| Exercise of option to repurchase common stock |
(8,342)
|
(8,342)
|
$ 0
|
$ 0
|
$ 0
|
(8,342)
|
0
|
| Inducement interest expense - debt conversion |
282,500
|
2,713,014
|
0
|
0
|
0
|
282,500
|
0
|
| Net loss |
(14,860,468)
|
(31,024,467)
|
0
|
0
|
0
|
0
|
(14,860,468)
|
| Ending balance at Nov. 30, 2019 |
$ (13,631,597)
|
$ (13,631,597)
|
$ 100
|
$ 399,316
|
$ (159)
|
$ 246,618,030
|
$ (260,648,884)
|
| Ending balance, shares at Nov. 30, 2019 |
|
|
99,888
|
399,315,351
|
159,011
|
|
|